AC Immune reports positive week-100 safety, immunogenicity in Phase 2 VacSYn trial of Parkinson’s vaccine ACI-7104
ACIU•Next steps for the program
Part 2 design is being finalized to test clinical activity, with FDA discussions on the development path planned for early 2027.
Phase 2 VacSYn week-100 results
AC Immune reported week-100 Part 1 Phase 2 VacSYn results for ACI-7104 in early-stage Parkinson’s disease.
Data were presented now, showing the study met its primary safety, tolerability, and immune-response goals.
Findings supported antibody activity in the central nervous system, with exploratory signals consistent with target engagement.
